Tharimmune to Present at the Microcap Conference 2025
-
Czech duo Muchova and Mensik win US Open mixed doubles title
-
Once a top export, prized Kashmir carpet fades
-
Japan's 'polka dot queen' artist Yayoi Kusama dies aged 97
-
Search for 1,000 missing after deadly Nepal-Tibet floods
-
Nepal-Tibet disaster: what we know
-
Park So-yeon first woman to play for eSports powerhouse South Korea
-
China deploys record number of ships around Taiwan as pressure grows
-
Yayoi Kusama: Japan's kaleidoscopic, troubled 'polka dot queen'
-
Ruthless Bayern target treble as rivals reboot on Bundesliga return
-
Euro champ Hunt 'on her toes' against world's best in Zurich 100m
-
What experts know so far about Nepal's deadly floods
-
Asian chip firms lifted by Nvidia forecast but broader markets struggle
-
UEFA set to withdraw FIFA boycott threat ahead of Champions League draw
-
Search for missing after Nepal-Tibet floods kill 165
-
Sumo moves to beat Japan summer heat as temperatures rise
-
Qantas says profits slump as fuel costs surge
-
'Be more honest': Markets crave clarity from cryptic Fed chair
-
Lofty bond yields, Bessent's intervention pose challenge to Fed's Warsh
-
Climate change leaves its mark on America's largest reservoir
-
The foreigners missing in Nepal's flash floods
-
CIA director warned Russia not to attack NATO members: US media
-
Bond yields are surging: Here's why that could spell trouble
-
Search for missing after Nepal-Tibet floods kills at least 160
-
Fed's Cook rejects Trump mortgage fraud claims
-
Meta, US states agree $18 bn settlement in landmark teen safety case
-
Police probe 'assault allegations' after Carse's nightclub incident
-
What scientists know so far about Nepal's deadly floods
-
How we might hear new Dolly Parton music in the future
-
US general visits Colombia to discuss war on drugs
-
Nvidia doubles revenue, forecasts even more AI spending
-
Meta settlement puts social media industry on notice: 'There will be more'
-
Canada renews push to boycott US products
-
NFL owners approve record Seahawks sale
-
Savio scores on debut as Spurs set-up League Cup tie with Liverpool
-
Nigerian armed groups net nearly $6 mn in ransoms: study
-
Brazil sues Discord over child safety measures, demands $100 mln in damages
-
Savio scores on debut as Spurs advance in League Cup
-
Alberta NDP Urges Smith to Postpone Separation Vote Amid Trade War
-
Mbappe hits treble as Real Madrid thrash Real Sociedad
-
Fenerbahce stun Lyon in Champions League as AEK crush Levski
-
At Dollywood, superfans honor the late singer and local hero
-
Why Global Finance Still Relies on Wall Street Despite Diversification Trends
-
Stocks mixed as oil drops, US inflation stays high
-
Bethlehem Father Seeks Aid for Special Needs Children Amid Health Crisis
-
Bolivia's Paz appoints new economy minister amid bailout talks
-
LIV Golf to lay off majority of staff
-
US designates UK-based Palestine Action as foreign 'terrorist group'
-
How narwhal 'scientists' track Arctic warming
-
'Rocky Horror Picture Show' star Tim Curry dead at 80
-
Iran says US sanctions will achieve nothing
Tharimmune to Present at the Microcap Conference 2025
BRIDGEWATER, NJ / ACCESS Newswire / January 27, 2025 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company committed to pioneering therapies in immunology and inflammation, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J.
Management will deliver a corporate presentation and engage in one-on-one meetings with institutional and individual investors to discuss the company's recent developments, growth strategy, and investment opportunities.
Event: The Microcap Conference 2025
Location: Studio 4, Borgata Hotel Casino & Spa
Date: Thursday January 30, 2025
Time: 10:00 AM Eastern Time
Investors interested in meeting with management can register for the conference here.
About Tharimmune
Tharimmune, Inc. is a clinical-stage biotechnology company developing a diverse portfolio of therapeutic candidates in immunology, inflammation and oncology. Its lead clinical asset, TH104, aims to suppress chronic pruritus associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease with no known cure. The expanded pipeline includes TH023, an oral TNF-alpha inhibitor, offering a new approach to treating autoimmune diseases. Tharimmune is also advancing early-stage multi-specific biologics targeting unique epitopes against multiple solid tumors. The company has a license agreement with OmniAb, Inc. to access their antibody discovery technology for targeting specified disease markers. For more information, please visit: www.tharimmune.com.
Contacts
Tharimmune, Inc.
[email protected]
Alliance Advisors IR
Tirth T. Patel
[email protected]
212-201-6614
Contact Information
Tirth Patel
Alliance Advisors IR
[email protected]
1-212-201-6614
SOURCE: Tharimmune Inc.
View the original press release on ACCESS Newswire
W.Morales--AT
